Erytech Pharma SA
PAR:PHXM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Erytech Pharma SA
PAR:PHXM
|
FR |
|
ViewRay Inc
OTC:VRAYQ
|
US |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PHXM's stock price target?
Not Available
PHXM does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Erytech Pharma SA?
Projected CAGR
-39%
Over the last 1 year, the compound annual growth rate for Revenue has been 59%. The projected CAGR for the next 3 years is -39%.